Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation (ASPEN)

This study has been terminated.
(recruiting problems)
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens Identifier:
First received: February 28, 2011
Last updated: May 11, 2016
Last verified: May 2016
Term and near term newborns can present acute respiratory distress syndrome (RDS). Surfactant treatment has been shown effective in reducing mechanical ventilation and oxygen treatment durations in the preterm newborn. Whether surfactant treatment is beneficial for term and near term newborns is unknown. The purpose of this study is to compare surfactant treatment vs. nasal continuous positive airways pressure in the newborn between 35 and 41 weeks of gestation with RDS within the first 24 hours of life. The study's primary endpoint is "survival with no oxygen treatment at 72 hours of life". The secondary endpoints are: death, surfactant treatment, pneumothorax, secondary infections, pulmonary hypertension, inhaled nitric oxide treatment, fluid loading treatment, vasopressive amines treatment, mechanical ventilation duration, nCPAP treatment duration, Oxygen treatment duration, Oxygen treatment at 28 days of life, hospitalization duration and treatment strategy cost.

Condition Intervention Phase
Acute Respiratory Distress Syndrome
Procedure: Surfactant instillation
Procedure: nCPAP
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Surfactant Treatment Compared to Nasal Continuous Positive Airway Pressure for the Management of Respiratory Distress Syndrome in the Newborn Between 35 and 41 Weeks of Gestation

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire, Amiens:

Primary Outcome Measures:
  • Succes of the procedure [ Time Frame: 72 hours of life ]
    survival without any oxygen treatment

Secondary Outcome Measures:
  • Morbidity associated to the management of a newborn with RDS in a neonatal intensive care unit [ Time Frame: Every 8 hours of life between birth and 72 hours of life. Then every day until neonatal intensive care unit discharge. ]
    • Death
    • Surfactant treatment,
    • Pneumothorax,
    • Secondary infections,
    • Pulmonary hypertension,
    • Inhaled nitric oxide treatment,
    • Fluid loading treatment,
    • Vasopressive amines treatment,
    • Mechanical ventilation duration,
    • nCPAP treatment duration,
    • Oxygen treatment duration,
    • Oxygen treatment at 28 days of life
    • Hospitalization duration
    • Treatment strategy cost

Enrollment: 19
Study Start Date: March 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Early strategy
Intratracheal poractant alpha (Curosurf®) after tracheal intubation
Procedure: Surfactant instillation
Intra-tracheal poractant alpha instillation after tracheal intubation
Active Comparator: Delayed strategy
Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
Procedure: nCPAP
Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.

Detailed Description:
Newborn between 35 and 41 weeks of gestation with RDS within the first 24 hours of life, treated with nCPAP and a FiO2 ≥ 30% are eligible. Randomisation is stratified by centre and 2 age groups (35-36 weeks of gestation and 37-41 weeks ogf gestation). One arm will receive surfactant treatment after tracheal intubation. The second arm will continue nCPAP. A rescue treatment is used in the second arm if FiO2 > 60%. In each arm the newborn is weaned from mechanical ventilation and oxygen treatment as soon as possible. The primary outcome of the study is the success of the procedure defined as "survival without any oxygen treatment" at 72 hours of life.

Ages Eligible for Study:   up to 1 Month   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Gestational age between 35 and 41 weeks of gestation
  • < 24 hours of life
  • Nasal Continuous Positive Airways Pressure (nCPAP) for more than 1 hour
  • FiO2 ≥ 30% with nCPAP and a target post-ductus arteriosus SpO2 >92%
  • Written consent of the parents

Exclusion Criteria:

  • FiO2 > 60% with nCPAP, ou FiO2 > 40% for 3 consecutives hours whatever the respiratory support
  • Life threatening congenital pathology
  • Congenital cardiopathy (except patent ductus arteriosus)
  • Shock defined as systemic hypotension (mean blood pressure <10th percentile of the normal range for birth weight and postnatal age) with at least 3 of the following criteria for decrease perfusion: 1) tachycardia (heart rate > 160 beats/min); 2) abnormal peripheral pulses; 3) modified extremities coloration; 4) prolonged capillary refill time > 3 seconds; 5) urine output < 1 ml/kg/h
  • Blood gas pH < 7.19 and / or PCO2 > 65 mmHg
  • Apgar score ≤ 3 at 5 minutes of life
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01306240

Amiens University Hospital
Amiens, Picardie, France, 80054
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
  More Information

Responsible Party: Centre Hospitalier Universitaire, Amiens Identifier: NCT01306240     History of Changes
Other Study ID Numbers: PHRCIR09-DR-TOURNEUX
Study First Received: February 28, 2011
Last Updated: May 11, 2016

Keywords provided by Centre Hospitalier Universitaire, Amiens:
Infant newborn
Infant preterm
Acute respiratory distress syndrome
Hyaline Membrane disease
Newborn acute respiratory distress syndrome (ARDS)

Additional relevant MeSH terms:
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury
Pulmonary Surfactants
Poractant alfa
Respiratory System Agents processed this record on May 24, 2017